Ginkgo Bioworks Holdings (DNA)vsRevolution Medicines Inc (RVMD)
DNA
Ginkgo Bioworks Holdings
$7.88
+0.51%
HEALTHCARE · Cap: $454.55M
RVMD
Revolution Medicines Inc
$190.95
-3.04%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Ginkgo Bioworks Holdings generates 17746% more annual revenue ($132.42M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -219.6%. DNA earns a higher WallStSmart Score of 31/100 (F).
DNA
Avoid31
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-28.8%
Fair Value
$7.26
Current Price
$7.88
$0.62 premium
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -69.2% — below average capital efficiency
Trading at 15.7x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : DNA
The strongest argument for DNA centers on Price/Book.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : DNA
The primary concerns for DNA are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
DNA profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.
DNA carries more volatility with a beta of 1.77 — expect wider price swings.
DNA is growing revenue faster at -48.5% — sustainability is the question.
DNA generates stronger free cash flow (-47M), providing more financial flexibility.
Bottom Line
DNA scores higher overall (31/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ginkgo Bioworks Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide range of sectors, including pharmaceuticals, agriculture, and industrial biotechnology. The company's innovative platform streamlines cellular design and manufacturing, positioning Ginkgo as a key player in addressing critical global challenges such as climate change and food security. With a strong focus on sustainable biotechnology solutions, Ginkgo is well-equipped to tap into the increasing market demand for bio-based alternatives, highlighting its potential for significant growth and transformative impact across various industries.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?